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Hippocampal oscillations recorded under urethane anesthesia are proposed to be modulated by anxiolytics. All classes of clinically
effective anxiolytics were reported to decrease the frequency of urethane theta; however, recent findings raise concerns about the
direct correlation of anxiolysis and the frequency of hippocampal theta. Here, we took advantage of our two inbred mouse strains
displaying extremes of anxiety (anxious (AX) and nonanxious (nAX)) to compare the properties of hippocampal activity and to
test the effect of an anxiolytic drugs. No difference was observed in the peak frequency or in the peak power between AX and nAX
strains. Buspirone (Bus) applied in 2.5mg/kg decreased anxiety of AX but did not have any effect on nAX as was tested by elevated
plusmaze and open field. Interestingly, Bus treatment increased hippocampal oscillatory frequency in the AX but left it unaltered in
nAXmice. Saline injection did not have any effect on the oscillation. Paired-pulse facilitation was enhanced by Bus in the nAX, but
not in the AX strain. Collectively, these results do not support the hypothesis that hippocampal activity under urethane may serve
as a marker for potential anxiolytic drugs. Moreover, we could not confirm the decrease of frequency after anxiolytic treatment.
1. Introduction
Anxiety disorders are among themost abundant affective dis-
orders, with a prevalence of 1% in theWestern countries. The
neurochemistry behind this set of conditions are relatively
well described: the imbalance of the serotoninergic system
has been implicated in regulating permanently elevated
anxious mood, and a prominent class of anxiolytic drugs
used in the clinic exert their action via the serotonergic
system including serotonin reuptake inhibitors and agonists
of the serotonin 1A receptor (5-HT1AR) [1, 2]. This receptor
is most abundant in the hippocampal CA1 [3, 4], suggesting
a primary role of this brain part in regulating anxiety.
Brain oscillations are thought to govern cognitive pro-
cesses, providing temporal functional linkage between dif-
ferent brain parts and allowing the temporal separation of
functionally distinct neuronal assemblies. Among the rich
repertoire of the prominent hippocampal oscillations, theta
activity is implicated in various cognitive processes, including
locomotion, learning and memory, and alert (fear and anxi-
ety) [5, 6]. This rhythm is subject to serotonergic influences
originating in the raphe nuclei [7–11]. Of particular interest
here, almost all classes of clinically effective anxiolytics and
compounds in the preclinical stage reduce the frequency of
hippocampal theta activity elicited by stimulation of the retic-
ular formation in freely behaving or anesthetized animals
[12]. Notable exception includes direct bilateral histamine
infusion into the lateral septum, which decreased anxiety-
like responses in two models of anxiety, the elevated plus
maze and novelty-induced suppression of feeding test in rats,
but, instead of decreasing, the same infusion significantly
increased hippocampal theta frequency elicited by reticular
stimulation in urethane-anesthetized rats [13]. Similar results
were reported for direct septal infusion of muscimol, which
also increased theta frequency evoked by brainstem stim-
ulation and reduced anxiety-like behaviors [14]. Moreover,
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if the above hypothesis holds true, then compounds that
generate anxiety (anxiogenics) should increase hippocampal
theta frequency. In contrast, two benzodiazepine receptor
inverse agonists and an𝛼2 noradrenergic receptor antagonist,
all having strong anxiogenic effect, do not have any effect on
hippocampal theta [15].
In this study, we took advantage of the two inbred
mouse lines we breed in our laboratory to test the effect
of an anxiolytic on hippocampal theta. We also tested the
hypothesis that if theta frequency is in correlation with
anxious phenotype, then these mice will show different theta
frequency. These strains show extremes in anxiety-related
behavior in the open field, elevated plus maze, and light/dark
test [16].
2. Materials and Methods
2.1. Animals. Inbred mouse strains having either high or
low anxiety level (AX and nAX) were bred in our animal
facility. These strains were originally developed at EGIS
Pharmaceuticals Co. (Budapest, Hungary) by bidirectional
inbreeding based on anticipatory anxiety [16]. Male mice of
2.5–3 months were housed individually under a light/dark
12 h cycle (lights on at 08:00) at 24 ± 1∘C and given ad
libitum food and water. Mice were handled for 7 days prior to
testing, the procedure is described byHurst andWest [13]. For
the experiments, 55–59th generations were used. The study
conformed to EU directive 2010/63/EU and was approved
by the regional Station for Animal Health and Food Control
under Project License XXXI/2012.
2.2. Behavior Tests
2.2.1. Elevated Plus Maze. The elevated plus maze apparatus
(EPM) was made of stainless steel (painted matt black)
consisting of two opposite open arms (35 cm × 7 cm) and
two opposite closed arms surrounded by 15 cm high walls
of the same dimensions. The middle section that allows the
animal to transit from arm to arm consisted of a square
with dimension of 7 cm × 7 cm. The apparatus was elevated
50 cm from the floor and the open arms were equipped with
1.5 cm × 1.5 cm ledges to ensure that no animals would fall
off the maze. Each mouse was placed in the central square
facing an open arm and the behavior was recorded for 5min.
Before each test, the apparatus was cleared with 20% (v/v)
alcohol and wiped thoroughly to eliminate the residual odor.
The behavior of the mice was recorded and analyzed with
an EthoVision software package (EthoVision XT 8.5 Noldus
Technology, The Netherlands).
2.2.2. Open Field Test. The open field (OF) arena consisted
of circular shape (Ø 92 cm) plastic arena with 40 cm high
black wall. Two 55W light bulbs were positioned 50-50 cm
above the center of the arena, which were the only source
of illuminations in the testing room. The behavior was
recorded for 5min and analyzed offline using EthoVision.
TheOF arenawas divided into centrum (diameter 77 cm) and
periphery zones.
2.3. Electrophysiology. Briefly, mice were anesthetized with
1 g/kg urethane i.p. and placed in a stereotaxic frame. Under
anesthesia, a multichannel electrode having 16 Pt/Ir contact
points separated by 100 𝜇m(the impedance of a 15𝜇mcontact
point is between 300–700 kOhm) and insulatedwith Formvar
(Neuronelektro´d kft., Budapest, Hungary) was lowered into
the dorsal hippocampus (AP, −2.0mm; 𝐿, +2.0mm; 𝐻,
−2.2mm) and a FHC concentric bipolar stimulating elec-
trode (Bowdoin, ME, USA) was lowered in the contralateral
hippocampus (AP, −2.0mm; 𝐿, −2.0mm; 𝐻, −5.8mm). The
location of the recording electrode was set by continuously
monitoring the local field potential (LFP) activity. Similarly,
the coordinates of the stimulation electrode were set to evoke
the largest response. Hippocampal 𝜃 rhythm was evoked by
a brief tail pinch. Field EPSPs were evoked by a bipolar
constant current paired-pulse stimuli separated by 50ms
delivered every 20 sec with an AM Systems isolated pulse
stimulator (Model 2100, Carlsborg, WA, USA). To establish
baseline amplitude levels, the current used for paired-pulse
stimulation was adjusted to obtain ∼30% of the maximal
amplitude under control conditions. One hour of recording
was used to establish baseline frequency and amplitude
measures followed by the injection of saline or buspirone.
Theta was evoked for at least 3 times before and after
i.p. injection. Evoked oscillations usually decayed after 45–
90 sec., and we waited for at least 60 sec. before applying
the following tail pinch. Paired-pulse stimulation was applied
right before and after ≈45min of i.p. injection.
2.4. Analysis and Statistics. Hippocampal LFP activity was
preamplified by a Plexon headstage (Dallas, TX, USA) and
amplified 100x and filtered (1–5000Hz) with an AM Systems
model 2100 differential amplifier and digitized with an A-D
converter (1401 micro 3, 15-kHz sampling rate, Cambridge
Electronic Design, Cambridge, UK) and commercially avail-
able software (Spike2, Cambridge Electronic Design). Power
spectral analyses of hippocampal LFP were performed on
20-s sweeps following the onset of each tail pinch. Changes
in power and peak frequency in response to drug treatment
were assessed by paired 𝑡-test unless otherwise indicated.
Electrophysiological features between strains were evaluated
by using independent 𝑡-test. For behavioral data, independent
𝑡-test or paired sampled 𝑡-test was used as indicated in the
Results. A 𝑃 level of ≤0.05 was considered significant.
3. Results
3.1. Behavior
3.1.1. Elevated Plus Maze. AX and nAX mice were subjected
to elevated plus maze in order to determine their level of
anxiety. There was a robust difference between AX and nAX
both in the total time spent in the open (110 ± 12 sec. versus
193 ± 5; 𝑃 ≤ 0.001, independent 𝑡-test, 𝑛 = 8, 10) and closed
(129±11 sec. versus 57±3 sec.;𝑃 ≤ 0.001, independent 𝑡-test)
arms, indicating difference in anxious phenotype. Another
cohort ofmice was tested 30min following bus injection.This
dose of the anxiolytic was only effective in the AX strain, as
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Figure 1: Buspirone decreased anxiety of AX mice in the elevated plus maze. A nonsignificant increase in the time spent in the open arm (a)
and a significant decrease in the time spent in the closed arm (b) were induced by buspirone. There was no effect of buspirone treatment on
nAX mice neither in the time spent in the open (c) nor in the closed (d) arm. **𝑃 ≤ 0.01, 𝑡-test.
treated mice spent less time in the closed arm compared to
untreated counterparts (81 ± 10 sec; 𝑃 ≤ 0.01, independent
𝑡-test, 𝑛 = 6). There was no difference between untreated and
Bus treated nAX mice (200 ± 5 sec. for open arm, 51 ± 5 sec.
for closed arm; 𝑛 = 5, Figure 1).
3.1.2. Open Field Test. Anxious behavior was also assessed by
open field test. We observed a significant difference in the
time spent in the center of the arena (55±2 sec. for AX versus
71 ± 4 sec. for nAX; 𝑃 ≤ 0.05, independent 𝑡-test; 𝑛 = 33
and 28, resp.) and in the periphery (245±2 sec. for AX versus
229 ± 4 sec. for nAX; 𝑃 ≤ 0.05, independent 𝑡-test) between
control mice. Bus treatment significantly elevated the time
exploring the center (80 ± 7 sec.; 𝑃 ≤ 0.01 versus control,
independent 𝑡-test), while it decreased the time spent in the
periphery of the arena (220 ± 7 sec.; 𝑃 ≤ 0.01 versus control,
independent 𝑡-test) in the AX mice (𝑛 = 6), a clear sign of
anxiolysis. On the other hand, the sameBus treatment did not
modify the behavior of nAX mice (time in center: 54 ± 6 sec;
time in periphery 246 ± 6 sec; 𝑛 = 10, Figure 2).
3.2. Hippocampal Theta. Urethane anaesthetized mice were
subjected to a brief tail flick which evoked prominent oscilla-
tion in the CA1 with frequency between 2.6 and 3.5Hz. This
theta activity lasted for several seconds, as is shown at Figures
3, 4, and 5. Theta activity under urethane influence has lower
frequency compared to unanesthetized conditions. We did
not observe any difference in the peak frequency nor in the
peak power of theta between AX and nAXmice (2.7 ± 0.2Hz
for AX versus 2.9 ± 0.3Hz for nAX; 0.015 ± 0.004mV2 for
AX versus 0.015 ± 0.005mV2 for nAX; 𝑛 = 11 and 11, resp.;
Figure 3).
After several tail flick epochs, saline (control) or bus-
pirone was injected intraperitoneally, and theta was evoked
every 2-3 minutes. No change was seen in the oscillation
following saline application (2.8 ± 0.2Hz before and 2.7 ±
0.2Hz after for AX; 2.9 ± 0.2Hz before and 2.8 ± 0.3Hz after
for nAX; 𝑛 = 5, 5, resp.; data not shown). In contrast, peak
frequency continuously increased in the AX mice having
received buspirone. The change peaked at 15–20min after
Bus application and remained for the rest of the recording
(2.9 ± 0.3Hz before versus 3.4 ± 0.2Hz after; 𝑃 ≤ 0.05, paired
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Figure 2: Buspirone decreased anxiety of AX mice in the open field test. An increase in the time spent in the center (a) and a decrease in
the time spent in the periphery (b) were induced by buspirone. There was no effect of buspirone treatment on nAX mice neither in the time
spent in the center (c) nor in the periphery (d). **𝑃 ≤ 0.01, 𝑡-test.
𝑡-test; 𝑛 = 6; Figure 4). No effect of Bus on the peak theta
frequency was detected in the nAX strain (2.8±0.2Hz before
versus 2.9 ± 0.2Hz after; 𝑛 = 6; Figure 5). Buspirone did
not alter the peak power of the evoked theta neither in AX
(0.018±0.005mV2 before versus 0.016±0.006mV2 after) nor
in nAX (0.013 ± 0.004mV2 before versus 0.011 ± 0.006mV2
after).
3.3. Basal Synaptic Transmission and Paired-Pulse Facilita-
tion. Paired-pulse recordings were taken before and after
i.p. injection. Buspirone slightly decreased the amplitude of
evoked fEPSPs in both AX and nAX mice, as was reported
previously by O’Connor et al. [17]. We did not observe such a
great reduction, as is reported in that study (around 47% for
2.5mg/kg buspirone). Under our experimental conditions,
this dose reduced fEPSPs to about 95% of the initial value.
There was no difference between the two strains in this regard
(94% for AX and 96% for nAX; data not shown). Similarly,
no difference was found between the ratio of 2nd/1st evoked
fEPSPs of AX and nAX (1.37±0.04 for AX versus 1.4±0.06 for
nAX; 𝑛 = 11 and 11, resp.; Figure 6). Paired-pulse facilitation
(PPF) was not changed by saline injection (1.36 ± 0.03 before
versus 1.34 ± 0.06 after; 𝑛 = 5 for AX and 1.39 ± 0.05 before
versus 1.38±0.04 after; 𝑛 = 5). Interestingly, we saw a decrease
of PPF after Bus application in the AX strain, which was not
significant (1.38 ± 0.06 before versus 1.31 ± 0.12 after; 𝑛 = 6).
On the other hand, a significant increase of PPF was detected
in nAX strain followingBus administration (1.41±0.07 before
versus 1.56 ± 0.06 after; 𝑛 = 6; 𝑃 ≤ 0.05 paired 𝑡-test).
4. Discussion
Hippocampal theta activity was implicated to play a role in
regulating anxious mood [6]. Enhanced theta activity can
be recorded from rodents subjected to a potentially anxiety
provoking situation, like the open arm of the elevated plus
maze [18] and lesions of the septohippocampal pathway,
which drives theta oscillation, disrupts anxiety-like behavior
in tests measuring anxiety (elevated plus maze, open field,
and light/dark box), social interaction, and hyponeophagia
[19–21]. Serotonin can modulate theta through a number
of different receptors and pathways [22–25]. Of particular
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Figure 3: A brief tail pinch evoked a prominent oscillation (a), which was in the theta range (b).There was no difference in the peak frequency
(c) and in the peak theta power (d) between AX and nAX mice. Calibration bars are 10 sec. and 0.5mV.
interest, 5-HT1ARs are especially implicated in regulating
anxiety. Mice lacking this receptor subtype show a massively
elevated anxiety reaction [26–29]. Buspirone, a clinically
effective anxiolytic is an agonist of 5HT1AR, and other
anxiolytics, like benzodiazepines, exert their calming effects
through the 5HT1AR [30]. Recently, several papers have
questioned the direct correlation of hippocampal theta and
anxious phenotype, suggesting that the previous correlation
between anxiety level and theta frequency might be an
epiphenomenon. By using our inbred mouse strains with
different anxiety levels, we tested whether there is any
difference in the theta oscillation parameters of these mice
under urethane anesthesia.
Unlike in undrugged animals, theta oscillation emerges
at a lower frequency (2.5–6Hz) under urethane anesthesia
and is sensitive to atropine or scopolamine ([31, 32] reviewed
in [23]), independent of the method of evocation. This
type of oscillation is referred to as type 2 theta, which,
unlike the movement related Type 1 theta, is connected to
sensory processing [33, 34]. Based on several reports and
observation, it was proposed that nucleus pontis oralis (NPO)
stimulation evoked hippocampal theta can be used as a
screen for potential anxiolytic compounds, because all classes
of clinically effective anxiolytics decrease theta frequency.
Moreover, a hyperpolarization-activated cation (Ih) channel
blocker and an antiepileptic, which decrease evoked theta
but were not shown to reduce anxiety before, proved to be
anxiolytic in subsequent behavioral tests [35, 36], lending
additional support for the hypothesis.
We did not observe any difference in the peak frequency
nor in the peak power of theta between AX and nAX mice.
Since there is a robust difference in the anxiety-related behav-
ior between these strains, this observation does not support
the straightforward connection between hippocampal theta
and anxious phenotype. Moreover, the anxiolytic we have
used, buspirone, affected only AX mice in the current dose
and acute application (reduced anxiety) but, oddly, increased
hippocampal theta frequency. We did not observe any effect
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Figure 4: Representative local field potential traces showing activity before (black) and after (red) buspirone administration in the AX mice
(a). Power spectra of the two illustrative traces indicate a peak shift after buspirone. Buspirone caused a slowing of evoked oscillation (b) but
did not change the peak power of theta (c). Calibration bars are 1 sec. and 0.3mV. ∗𝑃 ≤ 0.05, paired 𝑡-test.
on nAX mice of this low concentration of buspirone. Impor-
tantly, we have used a different kind of approach for triggering
hippocampal theta, namely, tail pinch. The mechanisms
behind theta evoked by either tail pinch (sensory evoked) or
NPO stimulation seem to be the same. Both oscillations are
modulated by the serotonergic input arising from the septum.
Moreover, blockade of the caudal NPO abolishes sensory
evoked theta in the hippocampus [37], suggesting that the two
approaches to evoke theta share common final pathways.
Other groups have also raised concerns about the direct
relationship between evoked theta and anxiety level. Com-
pounds that enhance anxious mood (anxiogenics) failed to
affect NPO evoked theta [15]. In addition, an otherwise
anxiolytic treatment, histamine infusion into the brain failed
to reduce NPO stimulation evoked theta, showing the lack
of direct connection between the two phenomena [13]. A
recent paper describes a similar phenomenon that we have
found. Direct infusion of muscimol into the lateral septum
increased theta frequency evoked by brainstem stimulation,
but, importantly, it reduced anxiety-like behaviors [14]. It has
to be noted that hippocampal theta is usually recorded from
anaesthetized animals from more easily accessible dorsal
hippocampus. Interestingly, electrophysiological recordings
from freely moving, behaving 5HT1A KO mice, which have
increased anxious phenotype, have shown that theta is not
changed in the dorsal hippocampus but is elevated in the
ventral part of hippocampus in a novel environment [29].
Basal synaptic transmission was slightly reduced in both
strains by bus, similarly as was reported by O’Connor et al.
[17] for rats. We did not see such a great fEPSP amplitude
reduction as the authors did observe. A possible explanation
for this contradiction might be that the mentioned study has
used Wistar rats, not mice. Paired-pulse facilitation (PPF)
ratio was the same in the two strains, but the effect of bus on
PPF was divergent: the compound increased PPF in the nAX,
while it did not modify PPF in the AX strain. The reason for
this divergent effect is not clear. PPF is usually regarded as
an indicator of presynaptic function; however local inhibitory
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Figure 5: Representative local field potential traces showing activity before (black) and after (red) buspirone administration in the nAXmice
(a). Power spectra of the two illustrative traces do not indicate change after buspirone. Buspirone did not change the peak frequency of evoked
oscillation (b) nor did it change the peak power of theta (c). Calibration bars are 1 sec. and 0.3mV.
networks were also shown to regulate hippocampal PPF [38].
Sibille et al. [30] have examined a decreased CA1 PPF ratio
in slices taken from the 5HT1A KO animals, but this was only
significant at 10ms interstimulus interval (we have used 50ms
interstimulus interval in this study).However, the same group
reported on decreased PPF in the sameKO strain in the gyrus
dentatus using longer interstimulus intervals (ISI, 40–90ms),
but not at 10ms ISI [39]. Activation of the same receptor
therefore might lead to increase of PPF, as was observed in
the nAX animals. However, 5HT1A receptors are localized at
both pre- and postsynaptic sites in the CA1; therefore, slight
changes in the distributionmight lead to divergent functional
effects and different PPF ratio, as was seen in our mice.
5. Conclusion
In summary, we have found that two mouse strains having
robust difference in anxiety-related behavior do not display
difference in sensory evoked hippocampal theta and basal
synaptic transmission. However, buspirone increased theta
frequency only in AX strains, parallel to the anxiolytic effect.
We found difference in the effect of buspirone on PPF
between strains.
Highlights
(i) Elicited hippocampal oscillation under urethane
anesthesia is proposed to correlate with the level of
anxiety.
(ii) Anxious (AX) and nonanxious (nAX) mice display
robust difference in anxiety level, but no difference
was found in CA1 oscillation under urethane.
(iii) Buspirone (2.5mg/kg) is anxiolytic in the AX, but not
in nAX mice.
(iv) Buspirone increased frequency of sensory evoked
oscillation in the AX, but not in the nAX.
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Figure 6: Paired-pulse facilitation remained unchanged after saline application in both AX and nAX strains. Buspirone did not alter PPF in
the AX but increased that in the nAX mice. Insets show representative traces of AX (upper) and nAX (lower) paired-pulse fEPSPs recorded
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𝑃 ≤ 0.05, paired 𝑡-test.
(v) Paired-pulse facilitation was enhanced by buspirone
in the nAX, but not in the AX strain.
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